Haleos Labs Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target

Haleos Labs Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Haleos Labs shares trading at Rs.1,564 against a market capitalisation of Rs.477 Cr and a price-to-earnings multiple of Not meaningful. As a pharmaceuticals and life sciences name on the NSE and BSE, Haleos Labs enters the Haleos Labs Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.

Quarterly financials for Haleos Labs are not yet fully available on Univest’s data partners for this cycle; investors should track Screener.in and the NSE/BSE filings directly for the Haleos Labs Q1 Results FY27 result date and cross-check any figures before making investment decisions.

Get Free Investment Predictions and Haleos Labs Research at Univest

Haleos Labs (NSE: HALEOSLABS) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings ahead of the Haleos Labs Q1 Results FY27 season, forming the base against which the Haleos Labs Q1 Results FY27 estimates in this article are built. This Haleos Labs Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.

Haleos Labs Q1 FY27 Estimates

Metric	Detail
CMP	Rs.1,564
Market Cap	Rs.477 Cr
Results Date	July-August 2026 (indicative)
12-Month Target (Uniresearch Estimate)	Rs.1,580-1,783

Univest, a SEBI-Registered Investment Advisor, Tracks Haleos Labs Ahead of Q1 FY27 Results

Key Catalysts to Watch

1. CDMO Pipeline Visibility

Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Haleos Labs’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Haleos Labs share price target or faces renewed pressure.

2. New Product Approvals

New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Haleos Labs’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Haleos Labs share price target or faces renewed pressure.

3. Capacity Scale-Up

Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Haleos Labs’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Haleos Labs share price target or faces renewed pressure.

Download the Univest iOS App or Univest Android App to track Haleos Labs’s live price and Q1 FY27 result updates.

Key Risks to the Haleos Labs Q1 Results FY27 Outlook

• Pricing pressure in key export markets, particularly the US generics segment.
• Regulatory or plant compliance issues affecting supply continuity.
• R&D and capacity expansion costs weighing on near-term profitability.

Recent Performance Context

Detailed recent-quarter financials for Haleos Labs were not available from Univest’s data partners at the time of writing. Investors should check Screener.in or the company’s exchange filings for the latest verified numbers before the Q1 FY27 results.

Technical Analysis Ahead of Haleos Labs Q1 Results FY27

Haleos Labs shares last traded at Rs.1,564. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.

Share Price Target Based on the Haleos Labs Q1 Results FY27 Outlook

3-6 Month Target

Over a 3-6 month horizon, the Haleos Labs Q1 Results FY27 trailing-growth framework points to a range of Rs.1,535-1,660 for Haleos Labs, contingent on the Haleos Labs Q1 Results FY27 print matching or beating the trailing growth trend.

12-Month Target

The 12-month target (Uniresearch estimate) tied to this Haleos Labs Q1 Results FY27 view for Haleos Labs works out to Rs.1,580-1,783, built on the same trailing revenue growth trend and current valuation multiple. Tracking is how Univest research categorises the stock heading into Haleos Labs Q1 Results FY27, not a formal Buy or Sell call.

FY27-28 Outlook

Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Haleos Labs Q1 Results FY27 analysis would put Haleos Labs in a Rs.1,668-1,949 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.

What to Watch in the Haleos Labs Q1 Results FY27 Print

• Revenue and PAT versus the Haleos Labs Q1 Results FY27 estimate range in this preview.
• Management commentary on FY27 growth guidance and margin trajectory relevant to the Haleos Labs Q1 Results FY27 narrative.
• Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
• Pricing pressure in key export markets, particularly the US generics segment

Conclusion on Haleos Labs Q1 Results FY27

Haleos Labs enters the Q1 FY27 results season trading at Rs.1,564, with the 12-month Uniresearch target range of Rs.1,580-1,783 reflecting a tracking stance. Investors tracking the Haleos Labs Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.

FAQs on Haleos Labs Q1 Results FY27

When are Haleos Labs Q1 FY27 results expected?

Ans. Haleos Labs’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.

What is the Haleos Labs Q1 FY27 revenue estimate?

Ans. Detailed quarterly estimates are not available for Haleos Labs at this time; check Screener.in or the company’s exchange filings for verified numbers.

What is the Haleos Labs share price target?

Ans. The 12-month Uniresearch estimate for Haleos Labs share price target is Rs.1,580-1,783, based on trailing growth and current valuation multiples.

Is Haleos Labs a good buy before Q1 FY27 results?

Ans. Haleos Labs is tracking heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.

What should investors watch in Haleos Labs’s Q1 FY27 results?

Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.

Where can I track Haleos Labs share price live?

Ans. Haleos Labs share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.